Basic ®broblast growth factor (bFGF) can exert mitogenic and viability-promoting eects in a wide range of biological systems. The biochemical activities mediating the cell survival function of bFGF are largely unknown. We report here that exposure of ®broblasts to bFGF, which confers upon them increased survival, also causes at the same time an increase in cellular levels of the Mdm2 oncoprotein. Cells constitutively exposed to a bFGF autocrine loop are more refractory to killing by cisplatin. This increased chemoresistance coincides with elevated Mdm2 and reduced activation of the endogenous p53, resulting in inecient transcriptional activation of the bax gene promoter. Importantly, unlike Mdm2 accumulation in ®broblasts exposed to DNA damage, induction of Mdm2 by bFGF does not occur through a p53-mediated pathway. The role of p53 in DNA damageinduced apoptosis and the ability of Mdm2 to block p53-mediated cell death are well established. These ®ndings therefore suggest that induction of Mdm2 and the subsequent inhibition of p53 function may contribute, at least partially, to the anti-apoptotic eects of bFGF and possibly some other survival factors.
Introduction
Fibroblast growth factors (FGF) constitute a family of at least fourteen structurally related polypeptides, expressed in a wide variety of cells and tissues. FGFs are potent mitogens that stimulate proliferation, migration and dierentiation of cells of mesenchymal and neuroectodermal origin (Folkman and Klagsburn, 1987; Rifkin and Moscatelli, 1989) . Basic FGF (bFGF), the most abundant member of the FGF family, is highly expressed in a variety of cell types. Transfected NIH3T3 cells, expressing a chimeric bFGF modi®ed by addition of a signal peptide, undergo autocrine transformation accompanied by characteristic morphological and biochemical alterations (Rogelj et al., 1988; Yayon and Klagsbrun, 1990) .
The biological response of cells to FGF is mediated through speci®c, high-anity cell surface receptors (FGFR), which possess intrinsic tyrosine kinase activity and are phosphorylated upon binding of FGF (Coughlin et al., 1988) . The FGFR signal transduction pathway is only partially established.
FGF binding induces receptor dimerization , tyrosine kinase activation and autophosphorylation (Coughlin et al., 1988) , similar to what has been observed for other growth factor receptors (Ullrich and Schlessinger, 1990) . Identi®ed intermediates include phospholipase C (Mohammadi et al., 1991) , ERK1 and ERK2 (Bogoyevitch et al., 1994; Creuzet et al., 1995) , cortactin , Src (Landgren et al., 1995; , Shc and a 90 kDa protein identi®ed as 80K-H (Klint et al., 1995; Goh et al., 1996) .
Basic FGF has also been implicated as a survival factor for a variety of cells, where an autocrine mechanism may potentially mediate both proliferation and cell survival. For instance, bFGF can increase survival of neurons (Blottner and Baumgarten, 1992; Zawada et al., 1996) , quiescent ®broblasts (Tamm et al., 1991) and cAMP-stimulated rat ovarian granulosa cells (Aharoni et al., 1995) . Antisense inhibition of bFGF expression induces apoptosis in vascular smooth muscle cells (Fox and Shanley, 1996) . Furthermore, bFGF can protect endothelial cells against radiationinduced apoptosis in vivo and in vitro (Fuks et al., 1994) . However, although bFGF is a potent survival factor, the molecular mechanisms underlying this activity remain to be elucidated.
p53 is an important contributor to the regulation of apoptosis. Its overexpression can trigger apoptosis in a wide array of cell types (Yonish-Rouach et al., 1991 , 1994 Shaw et al., 1992; Johnson et al., 1993; Ryan et al., 1993; Keren Tal et al., 1995; Haupt et al., 1995; reviewed in Oren, 1994) . Depending on cellular context, wild type (wt) p53 may facilitate apoptosis upon withdrawal of certain survival factors (Lotem and Sachs, 1993; Gottlieb et al., 1994; Zhu et al., 1994; Blandino et al., 1995; Eizenberg et al., 1996; Xiang et al., 1996) , as well as in response to the excess activity of several viral and cellular oncoproteins (Debbas and White, 1993; Hermeking and Eick, 1994; Wagner et al., 1994; Wu and Levine, 1994) . Apoptosis induced by DNA damaging agents is particularly dependent on p53, especially at low to moderate doses of DNA damage Lowe et al., 1993a, b; Gottlieb et al., 1994) . p53 accumulation is observed after treatment of cells with a variety of DNA damaging agents (Maltzman and Czyzyk, 1984; Kastan et al., 1991; Fritsche et al., 1993; Zhan et al., 1993; Lu and Lane, 1993) . Its transactivation capacity is increased (Lu and Lane, 1993; Zhan et al., 1993) , resulting in selective activation of p53 target genes such as bax, waf1/cip1 and GADD45 Dulic et al., 1994; Kastan et al., 1992; Miyashita and Reed, 1995) .
One of the best studied p53 target genes is mdm2. p53 activates transcription of the mdm2 gene Barak et al., 1993; Wu et al., 1993; Otto and Deppert, 1993) . Moreover, Mdm2 protein levels are up-regulated in a p53-dependent manner by DNA damaging agents (Perry et al., 1993; Price and Park, 1994; Chen et al., 1994) . Full length Mdm2 protein, as well as several smaller forms thereof (Olson, 1993) , bind to p53. This binding renders p53 biochemically inactive, and also targets it for rapid degradation within the cell (Momand et al., 1992; Wu et al., 1993; Haines et al., 1994; Oliner et al., 1993; Barak et al., 1993; Zauberman et al., 1993; Chen et al., 1995; Haupt et al., 1997; Kubbutat et al., 1997) . Thus, activation of mdm2 gene expression by p53 probably drives a negative feedback loop, whereby cellular p53 activity is kept in check and the p53 signal is properly terminated (Wu et al., 1993; Barak et al., 1993; Picksley and Lane, 1993; Momand and Zambetti, 1997) . It is of note, however, that co-expression of p53 and Mdm2 in the same cell does not always result in detectable p53-Mdm2 complexes (Otto and Deppert, 1993; Finlay, 1993; Momand and Zambetti, 1996) . Hence, the ability of Mdm2 to inactivate p53 might be regulated in a cell context-speci®c manner.
Mdm2 overexpression can promote immortalization and transformation of primary cells (Finlay, 1993) . Its overexpression in NIH3T3 cells confers enhanced tumorigenic potential in immunode®cient mice (Fakharzadeh et al., 1991) . Furthermore, the mdm2 gene is ampli®ed in a variety of human tumors, most of which retain intact p53 genes (Oliner et al., 1992; Reifenberger et al., 1993; Ladanyi et al., 1993; Cordon-Cardo et al., 1994; Corvi et al., 1995) .
The primary contribution of Mdm2 overexpression to cancer is believed to be through elimination of the tumor suppressor function of p53. However, Mdm2 may also promote growth deregulation through p53-independent mechanisms. For instance, Mdm2 binds to and inactivates the pRb tumor suppressor protein (Xiao et al., 1995) , and presumably also the pRbrelated p107 protein (Dubs-Poterszman et al., 1995) . In addition, it binds directly and activates the E2F transcription factor (Martin et al., 1995) . These capabilities may underlie the ability of Mdm2 to enhance the transformed properties of cells lacking endogenous wt p53 (Dubs-Poterszman et al., 1995) .
In line with its impact on the biochemical activities of p53, Mdm2 can also abolish the biological eects of p53. In particular, Mdm2 can relieve p53-mediated growth arrest , as well as protect cells from p53-dependent apoptosis (Chen et al., 1996; Haupt et al., 1996) .
In the present study, we demonstrate that the ability of bFGF to protect cells from the apoptotic eects of serum starvation or DNA damage correlates with its ability to induce Mdm2 and partially compromise the transcriptional activity of p53. Induction of Mdm2 by bFGF occurs through a p53-independent mechanism. Mdm2 may therefore mediate some of the survivalpromoting eects of bFGF, particularly in the context of p53-dependent apoptosis.
Results

bFGF protects Rat1 cells from serum deprivationinduced apoptosis
The survival promoting eects of bFGF are cell context dependent. Whereas bFGF increases the Figure 1 bFGF inhibits the death of serum starved D5 cells without exerting mitogenic eects. Cells were seeded with or without tetracycline, as described under Materials and methods. Twenty-four hours later, the medium containing 10% fetal calf serum (FCS) was removed from the indicated plates and replaced by medium containing 0.1% FCS, with or without added bFGF (20 ng/ml). Forty-eight hours later cells were harvested and subjected to¯ow cytometric analysis. Cell cycle distribution (a) was determined by propidium iodide (PI) staining. The position of cells with sub-G1 DNA content, indicative of apoptosis, is denoted by the horizontal bar; the percentage of such cells out of the total population is listed for each culture. Quantitative analysis of BrdU incorporation (b) along with PI staining served to determine the fraction of cells actively engaged in replicative DNA synthesis during S phase. The positions of sub-populations at various stages of the cell cycle, as well as of sub-G1 apoptotic cells, are indicated. The number on the upper left side of each panel denotes the percentage of cells in active S phase viability of mouse ®broblasts under conditions of serum starvation (Tamm et al., 1991) , it can not protect Rat1 ®broblasts from the apoptotic eects of cmyc in the absence of serum (Harrington et al., 1994) . D5 cells are derivatives of Rat1, which express excess cyclin D1 in a tetracycline-repressible manner (Resnitzky et al., 1994) . When induced in the presence of low serum concentrations, this excess cyclin D1 increases the basal level of spontaneous apoptosis in the culture (Sofer-Levi and Resnitzky, 1996) . The ability of bFGF to protect D5 cells from such apoptosis was tested by¯ow cytometry. When cellular DNA is stained with propidium iodide (PI) following cell permeabilization, apoptotic cells can be distinguished by virtue of their sub-diploid (`sub-G1') DNA content (Darzynkiewicz et al., 1992) . As depicted in Figure 1a , incubation of D5 cells with 0.1% serum for 48 h drove a substantial fraction of the cells into apoptosis, even in absence of cyclin D1 induction. Induction of cyclin D1 by tetracycline removal resulted in a further increase of the apoptotic population from 23 to 40%. By contrast, addition of 20 ng/ml bFGF to the culture medium reduced the death of both noninduced and induced cells by about twofold.
In addition to being a survival factor, bFGF can also act as a potent mitogen. To ®nd out whether the anti apoptotic eect of bFGF on D5 cells is due to its mitogenic activity, cells were exposed to various culture conditions, pulsed with BrdU, and analysed in the FACS for the extent of BrdU incorporation as a function of DNA content (PI staining). As seen in Figure 1b , cultures maintained in 10% serum displayed a high fraction of S phase cells, amounting to 50% of the total in this particular experiment. On the other hand, placing the cells in 0.1% serum resulted in a sharp drop in S phase content, down to 0.2%. A sizeable fraction of the cells now exhibited a sub-G1 DNA content, in agreement with the data in Figure 1a . Remarkably, addition of bFGF was practically unable to promote entry of the cells into S phase (Figure 1b) , despite the signi®cant reduction in the proportion of apoptotic cells. Hence, the ability of bFGF to partially protect D5 cells from death in the absence of serum can be clearly uncoupled from its mitogenic eect. This suggests that the two biological eects of bFGF in this system are accomplished through distinct, at least partially non-overlapping biochemical pathways.
bFGF increases Mdm2 protein levels
It is plausible that the survival promoting eects of bFGF might be mediated, at least to a certain extent, by proteins capable of exerting anti-apoptotic activities. The Mdm2 protein has previously been shown to inhibit p53-dependent apoptosis (Chen et al., 1996; Haupt et al., 1996) , and to protect tumor-derived cells against the apoptotic eects of cisplatinum (Kondo et al., 1995) . Moreover, expression of the mdm2 gene can be stimulated by serum (Mosner and Deppert, 1994) , presumably through the action of speci®c growth factors. We therefore tested whether bFGF can alter Mdm2 protein levels. To that end, D5 cells were subjected to the same treatments as in Figure 1 . Cells growing in the continuous presence of 10% serum were compared to cells maintained for 22 h in low serum, either with or without added bFGF. Cell extracts were prepared, and steady state Mdm2 levels were determined for each extract through a combined immunoprecipitation-Western blotting (IP-Western) approach. As seen in Figure 2 , placement in 0.1% serum resulted in a dramatic drop in Mdm2 levels, as compared to cells growing in 10% serum. On the other hand, addition of bFGF to serum-deprived cells resulted in a considerable increase in Mdm2, irrespective of cyclin D1 induction. Furthermore, a faster migrating Mdm2 band also became apparent. In these cells 10% serum was a more potent inducer of Mdm2 than bFGF; however, in NIH3T3 cells bFGF was actually more eective than serum (data not shown).
To extend the correlation between bFGF activity and Mdm2 protein expression, we took advantage of NIH3T3 6-1 cells (Rogelj et al., 1988) . The NIH3T3 6-1 line was derived by stable transfection of NIH3T3 cells with a transgene encoding a chimeric protein, comprising a fusion between bFGF and an immunoglobulin signal peptide. Consequently, these cells are subject to a potent, constitutive autocrine stimulation by bFGF. As seen in Figure 3 , NIH3T3 6-1 cells were found to contain signi®cantly more Mdm2 protein than non-transfected NIH3T3 cells, suggesting that the signal transduction pathway triggered by bFGF indeed leads to an increase in cellular Mdm2. Further support for this conclusion was obtained through the use of suramin. Suramin, a polyanionic drug capable of blocking interactions between growth factors and their receptors, has previously been shown to interrupt the bFGF autocrine loop in NIH3T3 6-1 cells and suppress their transformed phenotype (Yayon and Klagsbrun, 1990) . As shown in Figure 3 , exposure to suramin caused a marked decrease in steady state Mdm2 levels, both in NIH3T3 and in NIH3T3 6-1 cells. The ability of suramin to quench Mdm2 accumulation in NIH3T3 suggests that maintenance of basal Mdm2 levels may also rely on interactions of serum growth factors with cognate receptors.
Figure 2 bFGF elevates Mdm2 protein levels in D5 cells. D5 cells were seeded and treated as described in Figure 1 , except that cells were harvested 22 h after transfer to 0.1% serum with or without bFGF. Following extraction and determination of protein concentration, aliquots of each extract containing 3 mg of protein were subjected to immunoprecipitation with an anti Mdm2 polyclonal serum, followed by Western blotting and probing with the same polyclonal serum (IP-Western). Cyclin D1 induction was performed by tetracycline withdrawal. C6=clone 6 cells, harboring a temperature sensitive p53 mutant and expressing high levels of rat Mdm2 as a consequence of p53 activation at 328C Induction of Mdm2 by bFGF does not require functional p53
So far, signal-dependent Mdm2 accumulation has been studied only in the context of the p53 response, where activation of p53 (e.g. by DNA damage) can result in transcriptional activation of the mdm2 gene (Perry et al., 1993; Chen et al., 1994) . By de®nition, such increase in cellular Mdm2 protein requires the presence of functional p53 in the cell. It was important to determine whether the observed induction of Mdm2 by bFGF also operates through the same p53-dependent mechanism. To that end, the ability of bFGF to cause Mdm2 accumulation was compared in NIH3T3 ®broblasts, containing functional wild type p53 (data not shown; see later) and in murine (10) 1 ®broblasts which do not express any p53 at all (Harvey and Levine, 1991) . As is clearly evident from Figure 4 , bFGF induced a pronounced accumulation of Mdm2 in both cell lines, irrespective of the presence of wild type p53. Hence, unlike what has been observed in cells exposed to DNA damage (Perry et al., 1993; Price and Park, 1994) , the bFGF-induced increase in Mdm2 is not mediated through the activation of p53.
Cells overexpressing bFGF are less sensitive to induction of apoptosis by DNA damage DNA damaging agents can trigger p53-mediated apoptosis. Mdm2 can protect cells against p53-mediated apoptosis (Chen et al., 1996; Haupt et al., 1996) , presumably through eliminating the biochemical activities of p53. Based on the data presented above, it was therefore reasonable to assume that excess bFGF activity and the consequent increase in Mdm2 may confer greater resistance to the induction of apoptosis by DNA damage. Cisplatin, a DNA damaging drug often used for cancer chemotherapy, induces p53 activation (Fritsche et al., 1993) . Moreover, Mdm2 overexpression has already been shown to confer upon a human glioblastoma line increased resistance to cisplatin-induced apoptosis (Kondo et al., 1995) . We therefore compared the induction of apoptosis by cisplatin in NIH3T3 and in NIH3T3 6-1 cells. As seen in Figure 5 , cisplatin had adverse eects on both cell types. However, whereas exposure of NIH3T3 to 10 mg/ml cisplatin for 48 h caused very extensive cell death (Figure 5a and c), the same treatment had a visibly milder eect in NIH3T3 6-1 (Figure 5b and d) . This dierence between the two cell lines was also con®rmed in a quantitative assay, where PI staining followed by¯ow cytometry was used in order to assess the extent of apoptosis. As seen in Figure 6 , the cell cycle distribution of non treated NIH3T3 6-1 cells, growing in 10% serum, is indistinguishable from that of NIH3T3 cells. However, NIH3T3 6-1 cells were markedly less sensitive to induction of apoptosis by cisplatin. This was re¯ected by a drop of the sub-G1, apoptotic fraction from 74.5 to 34.6%. Furthermore, while practically no S phase cells were seen in treated NIH3T3 cells, consistent with the activation of the p53-dependent G1/S checkpoint (Kuerbitz et al., 1992) by cisplatin, S phase cells were still present in treated NIH3T3 6-1 cells (Figure 6 ). This suggests that distinct p53-dependent checkpoint functions of p53 are abrogated in cells possessing elevated Mdm2 in conjunction with excess bFGF activity. Similar observations were made with another DNA damaging agent, etoposide (data not shown).
The apoptotic eect of cisplatin on the two cell types was further con®rmed by performing TUNEL staining (Gavrieli et al., 1992) . As is evident from Figure 7 , cisplatin treated cultures exhibited a signi®cant number of TUNEL-positive cells (Figure 7b, d) , whereas very few positive cells could be observed in untreated cultures (Figure 7a, c) . Furthermore, in line with the FACS analysis, the proportion of apoptotic cells after 24 h of exposure to cisplatin was lower in NIH3T3 6-1 cultures than in NIH3T3 cultures (compare Figure 7d to b). It is of note that the fraction of TUNEL positive cells did not become very high even at later times; instead, there was a gradual accumulation of`ghosts' which have completely lost their DNA, as con®rmed by DAPI staining (data not shown).
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Figure 3 NIH3T3-derived cells overexpressing bFGF (NIH3T3 6-1) possess higher steady state levels of Mdm2. NIH3T3 and NIH3T3 6-1 cells were harvested without prior treatment or after addition of suramin (Sur.; ®nal concentration: 0.4 mM) to the culture 24 h before harvesting. Cells were harvested and processed by IP-Western Mdm2 analysis as in Figure 2 NIH-3T3 bFGF -+
-82 -Mdm2
10-1 -+ Figure 4 Induction of Mdm2 by bFGF is independent of the status of p53. NIH3T3 cells and (10)1 cells were incubated for 24 h in DMEM containing 0.1% FCS, either in the absence (7) or in the presence (+) of 20 ng/ml bFGF. Cells were harvested and extracted in protein sample buer. Extracts representing equal cell numbers (10 6 per lane for (10)1 cells and 2.4610 6 cells per lane for NIH3T3) were resolved directly on a 7.5% polyacrylamide SDS gel, and subjected to Western blot analysis with anti Mdm2 polyclonal serum
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Overall, the data indicate that bFGF can confer upon ®broblasts an increased resistance to DNA damage-induced apoptosis. Such protective eect might be exerted in part through elevation of Mdm2, presumably bringing about a reduction in the proapoptotic activity of p53 in such cells.
The transcriptional response of p53 to DNA damage is less ecient in cells overexpressing bFGF
The ability of p53 to serve as a sequence-speci®c transactivator of target genes is markedly enhanced upon exposure to DNA damage (Zhan et al., 1993 Hupp et al., 1995; Lu and Lane, 1993; Dulic et al., 1994; Barak et al., 1994) . This plays a crucial role in the induction of p53-mediated growth arrest or apoptosis. Moreover, not all target genes are stimulated to the same extent. Depending on cell type and the particular signals imparted to the cell, certain genes may respond more vigorously than others. It is conceivable that part of the decision between p53-mediated growth arrest and apoptosis depends on which genes are preferentially stimulated. In fact, analysis of p53 mutants suggests that there may exist two distinct sets of target genes, exempli®ed by Waf1 and bax, respectively; preferential activation of the ®rst set will favor a viable growth arrest, whereas activation of the second may favor apoptosis (Friedlander et al., 1996; Ludwig et al., 1996) .
Since overexpression of Mdm2 is known to downmodulate the transcriptional activity of p53 (Momand et al., 1992; Oliner et al., 1993; Chen et al., 1994 Chen et al., , 1995 , it was of interest to ®nd out whether bFGF-induced Mdm2 elevation might aect the ability of p53 to activate endogenous target genes, and whether there existed target gene selectivity. To that end, NIH3T3 and NIH3T3 6-1 cells were treated with cisplatin. Cells were harvested after 8 or 18 h, the former representing an early time point preceding the onset of detectable apoptosis, and the latter corresponding to a time when apoptosis has already started, but is still not very extensive. RNA was extracted and analysed for Waf1 and bax transcripts (Figure 8 ). It is notable that basal levels of both transcripts are higher in NIH3T3 6-1 cells than in NIH3T3, with a more prominent dierence seen in the case of Waf1. Waf1 gene expression is known to be induced by serum and other growth factors (Michieli et al., 1994; Canman et al., 1995) , and it is conceivable that bFGF may also exert a similar eect.
Upon treatment of NIH3T3 cells with cisplatin, a prominent increase of both Waf1 mRNA and bax mRNA was clearly seen within 8 h, with a slight further increase at 18 h (Figure 8a) . A rather dierent picture was revealed in NIH3T3 6-1 cells. Overall, the fold induction upon cisplatin exposure was signi®cantly lower for both Waf1 and bax transcripts. This was particularly evident at the 8 h time point. By this time, steady state levels of Waf1 mRNA increased only mildly. Remarkably, no change was detectable at all for bax mRNA. Hence, both the kinetics and the overall extent of induction of p53 target genes by DNA damage are compromised in NIH3T3 6-1 cells, and the inhibitory eect is more complete in the case of bax. This ®nding is consistent with the conjecture that bFGF-dependent Mdm2 accumulation interferes with the optimal activation of p53 by DNA damage.
Inecient activation of the bax promoter by cisplatin in NIH3T3 6-1 cells The data described above demonstrated that the two cell lines dier markedly with regard to the fold induction of p53 target gene transcripts in response to cisplatin. It was of interest to ®nd out whether this was due to a dierence in the ability of p53 to transactivate the promoters of these genes. To that end, NIH3T3 and NIH3T3 6-1 cells were transiently transfected with plasmids containing either the Waf1 promoter or the bax promoter, positioned in front of a ®re¯y luciferase reporter gene. Cisplatin was subsequently added to the culture medium, and luciferase activity was determined 18 h later. As seen in Figure 9a , cisplatin elicited a several fold increase in the activity of the Waf1 promoter in NIH3T3 cells, and this increase was not abrogated in NIH3T3 6-1 cells. The latter fact is at variance with the analysis of endogenous Waf1 mRNA (Figure 8a ), perhaps re¯ecting dierences between the accessibility of the Waf1 promoter to p53 when chromosomally integrated and when present in multiple copies on a plasmid. Remarkably, more pronounced dierences between the two cell lines were revealed when the ability of cisplatin to activate the bax promoter was assessed. Whereas a several fold induction was reprodicibly seen in NIH3T3 cells, the eect was much milder in NIH3T3 6-1 cells ( Figure  9b ). This observation, in agreement with the analysis of endogenous bax mRNA (Figure 8a ), further suggests that DNA damage fails to activate the bax promoter eciently in cells which overexpress bFGF and possess increased levels of Mdm2.
Discussion
The work presented here demonstrates that bFGF can serve as a survival factor for ®broblasts deprived of serum or exposed to lethal DNA damage, and suggests that this may occur in part through induction of Mdm2 accumulation, which in turn interferes with p53-dependent apoptotic responses. bFGF has already been Activation of p53 target genes by cisplatin in NIH3T3 and NIH3T3 6-1 cells. Sub con¯uent cultures of NIH3T3 and NIH3T3 6-1 cells were treated with 5 mg/ml cisplatin for the indicated periods. RNA was extracted, and aliquots containing 15 mg of each RNA were processed by agarose gel electrophoresis and Northern blotting, followed by probing with a combination of Waf1 and bax probes (a), or with a GAPDH probe as control (b) Figure 9 Activation of the Waf1 and bax promoters by cisplatin in NIH3T3 and NIH3T3 6-1 cells. NIH3T3 or NIH3T3 6-1 cells were seeded at a density of 0.5610 6 per 60 mm dish, transfected with 2 mg of either Waf1Luc (a) or pGL3-baxLuc (b) reporter plasmids, treated with cisplatin (5 mg/ml) and processed for analysis of luciferase activity, as described under Materials and methods. Results are presented as fold induction in cisplatin treated relative to untreated cultures. Each experiment was repeated twice in triplicate. The standard deviation is shown above each column shown to confer a survival advantage in a variety of biological systems. The data presented in Figure 1 provides strong evidence that the survival promoting eect of bFGF is distinct from its mitogenic eect. Hence, bFGF may simultaneously trigger multiple eector pathways, each of which may independently mediate a distinct biological response.
In serum-deprived Rat1 cells, the survival eect of bFGF is less complete than that of serum (Figure 1) . Interestingly, this correlates with a milder increase in Mdm2 levels (Figure 2 ). An ability to induce an elevation of Mdm2 may thus contribute, at least to some extent, also to the anti-apoptotic eect of factors contained within the serum. Our ®ndings do not imply that Mdm2 is the sole mediator of bFGF's survival function. In fact, engagement of receptor tyrosine kinases usually causes the simultaneous triggering of multiple downstream eector pathways. However, unlike for IGF1 and PDGF, triggering of the phosphatidylinositol 3-kinase pathway (Kauman-Zeh et al., 1997; Kulik et al., 1997 ) is unlikely to account for the anti-apoptotic eect of bFGF; hence, the contribution of Mdm2 to this eect may be more crucial in the case of bFGF.
We propose that bFGF-dependent augmentation of cellular Mdm2 levels confers greater resistance to p53-mediated apoptosis, presumably through down-modulating cellular p53 activity. In line with this notion, cells exposed to a potent bFGF autocrine loop appear to be partially compromised in their ability to respond to DNA damage by rapidly elevating the expression of p53 target genes. This is particularly the case for the bax gene; both accumulation of endogenous bax transcripts and activation of a transfected bax promoter are severely repressed in NIH3T3 6-1 cells.
The selective defect in Bax promoter transactivation might be related to the fact that p53 associates rather weakly with the p53 binding sites of this promoter, as compared to the sites found in the Waf1 promoter (Friedlander et al., 1996; Ludwig et al., 1996) . Consequently, higher cellular concentrations of p53 may be required for optimal activation of the bax promoter. In cells containing higher Mdm2 levels, as is the case for NIH3T3 6-1, the concentration of transcriptionally competent p53 may not reach the threshold required for bax activation. Yet, such reduced concentration may still suce for activation of the Waf1 promoter following DNA damage exposure. By contrast, the basal levels of bax and p21 expression are actually higher in NIH3T3 6-1 than in parental NIH3T3 cells. This may re¯ect p53-independent eects of bFGF, similar to those observed with serum stimulation (Michieli et al., 1994) .
Of particular signi®cance is the fact that p53 is not required for the induction of Mdm2 by bFGF. Such p53-independence can assure that bFGF continues to maintain elevated Mdm2 levels even when p53 is rendered temporarily inactive, thereby allowing a longer lasting and more tight anti-apoptotic eect. The classical p53-mdm2 negative feedback loop model Picksley and Lane, 1993; Otto and Deppert, 1993; Wu et al., 1993) may thus be modi®ed to incorporate external, p53-independent inputs such as bFGF ( Figure 10 ). Such inputs can probably regulate in a dominant manner the functional outcome of the autoregulatory loop, instead of allowing this loop to drive itself to exhaustion.
In conclusion, our ®ndings suggest a novel mechanism for the anti-apoptotic eects of bFGF, and perhaps some additional survival factors. It should be kept in mind, though, that the generality of this mechanism still needs to be further evaluated; not all survival factors are likely to act in the same manner. For instance, the anti-apoptotic eect of interleukin 3 in a lymphoid cell line is not accompanied by changes in Mdm2 expression (Canman et al., 1995) . Moreover, while the anti-apoptotic eect of Mdm2 has been convincingly demonstrated in the context of p53-mediated apoptosis (Chen et al., 1996; Haupt et al., 1996) , Mdm2 appears unable to protect against p53-independent apoptosis (R Maya and M Oren, unpublished data). Hence, elevation of Mdm2 is unlikely to account for survival eects exerted by bFGF on cells lacking wt p53. Nevertheless, the data suggest that the p53-Mdm2 autoregulatory loop might provide an attractive target for modulation of cell fate by external and internal signals.
Materials and methods
Cell culture D5 cells (Resnitzky et al., 1994) , were routinely grown in DMEM containing 10% fetal calf serum (FCS) and 2 mg/ ml tetracycline. For starvation experiments, 1.5610 6 cells were seeded per 10 cm dish in the presence of 10% FCS, with or without tetracycline. Twenty four hours later, the medium was replaced with starvation medium (0.1% FCS), with or without tetracycline. In the absence of tetracycline, cyclin D1 expression is induced (Resnitzky et al., 1994) . NIH3T3 and NIH3T3 6-1, previously designated NIHIgBNM6-1 (Rogelj et al., 1988) , were routinely grown in 10% bovine calf serum. All cells were maintained in a 5% CO 2 atmosphere.
Protein analysis
MDM2 was detected by immunoprecipitation with a polyclonal anti MDM2 rabbit serum , followed by Western immunoblotting using the same antibodies as probe. Western blot analysis of Mdm2 was done as described . Figure 10 Simpli®ed model illustrating the eect of bFGF on the p53-mdm2 autoregulatory loop. Activating and inhibitory eects are denoted by (+) and (7), respectively. bFGF is shown to induce Mdm2 in a p53-independent manner. The action of bFGF results in an increase in Mdm2 protein levels; however, it is presently unknown whether this occurs post-transcriptionally (as suggested by the model) or whether bFGF actually promotes mdm2 gene transcription
RNA extraction and analysis
Cellular RNA was extracted with the RNAsol TM B kit, according to the manufacturer's instructions (Biotecx Laboratories Inc. Texas, USA). Northern blot analysis was performed as described ; 15 mg of total RNA was loaded per lane.
Transfection and luciferase assay
For luciferase assays, 0.5610 6 NIH3T3 or NIH3T3 6-1 cells were seeded per 6 cm dish. The next day, cells were transfected with luciferase reporter plasmids driven by either the Waf1 or bax gene promoters, as described before (Friedlander et al., 1996) . The calcium phosphate precipitates were left on the cells for 12 h and then cells were exposed to a glycerol shock. Six hours later, cisplatin was added to a ®nal concentration of 5 mg/ml. Cells were harvested after 18 h of treatment. Luciferase assays were performed using a commercial kit (Promega, USA) in conjunction with a TD-20e luminometer (Turner, USA). Each experiment was done in triplicates and was repeated twice.
FACS analysis
FACS analysis was performed as previously described (Haupt et al., 1995; Sofer-Levi and Resnitzky, 1996) .
TUNEL
To end-label DNA strand breaks by the TUNEL method (Gavrieli et al., 1992) , adherent cells were trypsinized and combined with the non-adherent cells of the same culture. Cells were then deposited on a glass slide with the aid of a Cyto-spin, ®xed in paraformaldehyde (4%, in PBS) at room temperature for 30 min, washed twice in PBS, and then permeabilized by incubation in a solution of 0.1% Triton X-100, 0.1% sodium citrate for 2 min at 08C. TUNEL staining was done with the In-Situ Cell Death Detection Kit (Boehringer Manheim), using¯uorescein dUTP. Cells were visualized and pictures were taken under a¯uorescent microscope.
